Binocrit 8.000 UI is a pharmaceutical-grade medication containing Epoetin Alfa, a synthetic form of erythropoietin, intended to treat anemia associated with chronic kidney disease or chemotherapy. Known for its efficacy, this product meets rigorous regulatory standards for clinical applications.
- Physical Properties:
- Appearance: Clear, colorless solution for injection
- Active Ingredient: Epoetin Alfa
- Concentration: 8,000 IU
- Administration: Subcutaneous or intravenous injection
General Product Description
Introduction
Binocrit 8.000 UI (Epoetin Alfa) is a vital medication for individuals suffering from anemia, particularly those with chronic kidney disease or undergoing chemotherapy. Erythropoietin is crucial for stimulating red blood cell production in the bone marrow, which helps alleviate symptoms associated with anemia, such as fatigue and weakness.
The formulation of Binocrit provides a reliable means of managing anemia effectively, ensuring that patients can maintain their quality of life.
Key Features & Therapeutic Relevance
- Erythropoiesis-Stimulating Agent: Binocrit effectively stimulates red blood cell production, providing a therapeutic benefit for patients with anemia.
- Regulatory Compliance: Fully compliant with international regulations governing the use of erythropoiesis-stimulating agents in clinical practice.
- Established Safety Profile: Extensive studies and clinical trials back the safety and efficacy of Epoetin Alfa in treating anemia.
Product Specifications
- Appearance: Clear, colorless solution in vials
- Active Ingredient: Epoetin Alfa
- Concentration: 8,000 IU
- Administration Route: Subcutaneous or intravenous injection
- Storage Conditions: Store in a refrigerator (2°C to 8°C); do not freeze.
Indications & Usage
Binocrit 8.000 UI is indicated for:
- Treatment of anemia in patients with chronic kidney disease.
- Management of chemotherapy-induced anemia in cancer patients.
- Reduction of the need for red blood cell transfusions in surgical patients.
All applications should be guided by healthcare practitioners to ensure appropriate use and patient safety.
Dosage & Administration
The dosage of Binocrit varies based on indications and patient response:
- Chronic Kidney Disease: Typically initiated at 50-100 IU/kg administered 1-3 times per week.
- Chemotherapy-Induced Anemia: Dosing generally starts at 150 IU/kg given weekly.
Dosage adjustments should be made based on hemoglobin levels and clinical response.
Safety & Handling Guidelines
Handling Binocrit 8.000 UI requires adherence to safety protocols, including:
- Personal Protective Equipment: Use gloves and appropriate protective equipment when handling injectables.
- Infection Control: Follow standard infection control procedures during administration.
- Disposal Procedures: Dispose of used syringes and vials according to local regulations for hazardous waste.
Storage Information
- Temperature: Keep refrigerated between 2°C and 8°C.
- Stability: Protect from light; avoid freezing to maintain efficacy.
Legal & Safety Disclaimer
Binocrit 8.000 UI is intended for use under the supervision of qualified healthcare professionals. It is not for human or veterinary use outside the prescribed indications. Handling and administration must conform to national and international medical regulations.
FAQ Section
What is Binocrit used for?
Binocrit is used for treating anemia associated with chronic kidney disease and chemotherapy-induced anemia.
How is Binocrit administered?
It can be administered subcutaneously or intravenously, based on healthcare provider recommendations.
Is there a risk of side effects?
As with any medication, there can be side effects, which should be discussed with a healthcare provider prior to administration.
How should Binocrit be stored?
Store it in the refrigerator and protect it from light; do not freeze.
Who should determine the appropriate dosage?
A qualified healthcare professional should determine the dosage based on individual patient needs and response.
Reviews
There are no reviews yet.